Skip to main content
Premium Trial:

Request an Annual Quote

MRM Proteomics, PROOF Team on Chronic Disease Dx

NEW YORK (GenomeWeb News) – The Centre of Excellence for the Prevention of Organ Failure (PROOF) and MRM Proteomics announced today that they will partner on proteomic-based diagnostic tests for patients with chronic organ diseases.

The partners' goal is to develop blood-based tests that can help clinicians more effectively manage patients with heart, lung, and kidney diseases.

The non-profit PROOF Centre will apply its computational pipeline to guide the experimental design and data quality control and analysis needed for identifying protein signatures that can be used with other molecular signals to indicate heart, lung, and kidney disease.

MRM provides protein quantitation and proteomic services to biotech and diagnostic firms using multiple reaction monitoring-mass spectrometry technology. The firm's PeptiQuant MRM assays enable absolute quantitation of hundreds of proteins at a time from a single drop of blood.

"Our organizations’ offerings are clearly complementary in the field of protein biomarker discovery and validation," Andrew Munk, president and CEO of MRM, said in a statement. "The discovery, validation and implementation of biosignatures are complex processes. Partnering with the PROOF Centre will provide our customers with access to the PROOF Centre’s internationally recognized computational tools and capabilities to optimize the design and analysis of their mass spec based proteomic biomarker studies.”

Financial and other terms of the alliance were not disclosed.

Both the PROOF Centre and MRM are based in Vancouver, British Columbia.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.